Craneware (LSE:CRW), the healthcare software group and one of the larger constituents of the FTSE AIM All Share Index, saw its shares fall sharply in September 2026 after it reset guidance for the current financial year. Alongside its full-year results on 21 September 2026, the company took what it called a prudent view of Revenue for the year to June 2027, following a cyber incident first disclosed in July. The shares were down 23% at 1,030p by early afternoon on the day.
What the company does
Craneware provides software and Data Analytics to hospitals and health systems in the United States, helping them manage revenue, pricing, pharmacy spending and operational performance. Its Business is largely built on multi-year subscription contracts, which makes annual recurring revenue, or ARR, a key measure for investors. The group is led by chief executive Keith Neilson.
Latest developments
In July 2026 Craneware disclosed unauthorised access to a subset of its data environment. By the time of the September results, the company said the immediate impact had been contained and it was in a remediation phase, with investigations and regulatory reporting continuing. However, the full financial effects, including any impact on future customer engagement, were not yet known.
For the 2027 financial year the company now expects revenue of about $185 million, in line with current ARR. That compares with a previous expectation of $223.4 million. Craneware said it expected adjusted EBITDA margins in the mid-to-high 20% range for the year, aiming to return to above 30% in the 2028 financial year, when it expects growth to resume. Mr Neilson said the reset gave Stakeholders certainty and did not change the group's confidence in its long-term opportunity. Priorities include renewing long-term contracts, growing recurring revenue, sizing the cost base appropriately and maintaining solid cash generation.
Financial and Dividend picture
For the year to 30 June 2026, revenue was roughly unchanged at $206 million, while ARR rose 1% to about $185 million. Adjusted EBITDA increased 3% to $67.1 million, a Margin of around 33%. Cash at the year end was $54.8 million, and the company reported undrawn facilities including a revolving Credit facility. Craneware carried out a $25 million share buyback during the year, partly funded by bank borrowing, and held its total dividend for the year at the prior-year level.
Sector and index context
US healthcare technology has faced shifting hospital budgets and regulatory change, and commentators have also pointed to delays linked to the US 340B drug pricing programme as a Factor in Craneware's outlook. Within the FTSE AIM All Share Index, Craneware is one of the more established technology names, so a sharp share price move has a noticeable effect on the index's healthcare and technology weighting.
Key risks
The main uncertainties are the lasting commercial effect of the cyber incident, including potential customer churn or slower renewals, and any regulatory or legal costs. Margins are expected to fall in the 2027 financial year, and the higher bank Debt taken on to support the buyback reduces some Balance Sheet flexibility. US healthcare policy changes could also affect demand.
What to watch next
Investors will watch for updates on contract renewals and the remediation work, the company's next trading update, and evidence that ARR is holding at the guided level. Broker Berenberg, which rates the shares a buy, said it saw the $185 million base as a realistic starting point and forecast a 27% adjusted EBITDA margin for 2027.






Please wait processing your request...